Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease | Gut
Tofacitinib inhibits inflammatory cytokines from ulcerative colitis and healthy mucosal explants and is associated with pSTAT1/3 reduction in T-cells | American Journal of Physiology-Gastrointestinal and Liver Physiology
Levels of pro-inflammatory cytokines IL-1β, IL-6 and TNF-α and... | Download Scientific Diagram
TH17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identity | Science Immunology
Variation in Interleukin 6 Receptor Gene Associates With Risk of Crohn's Disease and Ulcerative Colitis - ScienceDirect
Interleukin-6: obstacles to targeting a complex cytokine in critical illness - The Lancet Respiratory Medicine
YAP Aggravates Inflammatory Bowel Disease by Regulating M1/M2 Macrophage Polarization and Gut Microbial Homeostasis - ScienceDirect
Interleukin-6, but not the interleukin-6 receptor plays a role in recovery from dextran sodium sulfate-induced colitis
Serum IL-6 and TNF-α levels of mice with DSS-induced colitis treated... | Download Scientific Diagram
STAT3 pathway and IL6/STAT3/S1PR1 amplification loop in IBD-CRC. | Download Scientific Diagram
Variation in Interleukin 6 Receptor Gene Associates With Risk of Crohn's Disease and Ulcerative Colitis - ScienceDirect
Immunopathogenesis of IBD: current state of the art | Nature Reviews Gastroenterology & Hepatology
Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases | SpringerLink
New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology | Nature Reviews Gastroenterology & Hepatology
Schematic model of IL-6/STAT3 pathway in inflammatory bowel disease.... | Download Scientific Diagram
Interleukin-6, but not the interleukin-6 receptor plays a role in recovery from dextran sodium sulfate-induced colitis
IL-6-Do You Really Know That?-CUSABIO
Compartmentalized Response of IL-6/STAT3 Signaling in the Colonic Mucosa Mediates Colitis Development
Frontiers | New Insights on CD8+ T Cells in Inflammatory Bowel Disease and Therapeutic Approaches
Il‐6 signaling in inflammatory bowel disease: Pathophysiological role and clinical relevance - Mudter - 2007 - Inflammatory Bowel Diseases - Wiley Online Library
JCM | Free Full-Text | Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products | HTML
Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease - ScienceDirect
Biological characteristics of IL-6 and related intestinal diseases
Frontiers | Serum Biomarkers for Inflammatory Bowel Disease
Modified Pulsatillae decoction inhibits DSS-induced ulcerative colitis in vitro and in vivo via IL-6/STAT3 pathway | BMC Complementary Medicine and Therapies | Full Text
Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study | PLOS ONE
Frontiers | IL-10 and IL-22 in Mucosal Immunity: Driving Protection and Pathology
